ALX Oncology Holdings Inc

Alx Oncology Holdings Inc is an American specialist healthcare company based in Burlingame, California. The company was founded in 2015 and operates as a clinical-stage immune-oncology facility, primarily engaged in developing therapies that allow patients to fight cancer, by bridging the innate and adaptive immune system. The firm went public in July 2020 and is listed on the NASDAQ GS, where it trades under the ticker ALXO. As of November 2020, the ALXO price chart showed a 52-week low of $28.01 and a 52-week high of $88.90, with a market cap of $2.52bn. ALX Oncology is involved in the development ALX148, a next-generation CD47-blocking therapeutic that has demonstrated promising clinical responses in the treatment of hematologic malignancies and solid tumours, in combination with leading anti-cancer agents. The firm is involved in various pre-clinical and clinical trials, in collaboration with partners such as MERCK and ZymeWorks, to develop treatments for various cancers in areas where it is believed that there is the greatest potential to address medical needs that are not currently being met. Are you looking to diversify your portfolio on eToro? Add this instrument to your watchlist and keep up to date with all the latest news and updates on the ALXO price chart.